|
|
News for:
|
|
For this drug, our server compiled this detailed Chemical Profile.
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
|
Click the Chemical Profile link above for detailed information.
Visit Betterchem's Drug Index for
- Exclusivity
Patents and market exclusivity
- Drug Information
Prescribing and other
information
- DMFs
Type 2 drug master files
- Databases
Free access to database search
- 21 CFR
FDA regulations for this drug
- Federal Register
FR search results for this drug
- Drug Recalls
For Rx's using this API
|
|
|
| |
FDA Approval Activities for this Drug
Actos (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg, Takeda NDA 21-073/S-021 6/11/03 7/8/03 7/8/03
Actos (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg, Takeda NDA 21-073/S-017 1/17/03 1/23/03
Actos (pioglitazone HCl) Tablets, Takeda NDA 21-073/S16 1/7/02 2/8/02
Actos (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg, Takeda North America, Inc NDA 21-073/S-018 12/3/02 12/9/02
Actos (pioglitazone) Tablets, Takeda NDA 21-073/S10 7/12/02 7/15/02 7/15/02
Actos (or pioglitazone HCl) oral Tablets, 15 mg, 30 mg, and 45 mg, Takeda NDA 21-073 7/15/99 7/28/99 7/28/99 6/30/00
Actos Indicated: for the improvement of glycemic control in patients with Type 2 diabetes as monotherapy, or in combination with a sulfonylurea, metformin or insulin when diet and the single agent does not result in adequate glycemic control. Actos (pioglitazone HCl) Tablets, Takeda Actos (pioglitazone HCl) Tablets, Takeda, Labeling Revision Actos (pioglitazone HCl) Tablets, Takeda Global, Labeling Revision | Pioglitazone Hydrochloride Tablets, Mylan Pharma, Tentative Approval | Pioglitazone Hydrochloride Tablets, Alphapharm, Tentative Approval | Actoplus Met (pioglitazone and metformin HCl) Tablets, Takeda Global, Approval | Pioglitazone Hydrochloride Tablet, Watson Labs, Tentative Approval | Pioglitazone Hydrochloride Tablets, Teva Pharma, Tentative Approval | Duetact (Pioglitazone HCI, Glimepiride) Combination Tablets, Takeda Global, Approval | Actos Tablet, Takeda Pharmaceuticals, Labeling Revision | Actoplus MET Tablet, Takeda Pharmaceuticals, Labeling Revision | Actos (pioglitazone HCl), Takeda Global, Labeling Revision
| ActoPlus Met (pioglitazone HCl plus metformin HCl) Global, Labeling Revision | Actos (pioglitazone HCl) tablets, Takeda Global, Labeling Revision | Actoplus Met (pioglitazone HCl + metformin HCl) fixed-dose combination tablets, Takeda Global, Labeling Revision | DUETACT (pioglitazone HCl + glimepiride) fixed-dose combination tablets, Takeda Global, Labeling Revision | Actos (pioglitazone HCl) Tablets, Takeda Global, Efficacy Supp. w/Clinical Data
Visit Betterchem's Drug Index for FDA's latest approval information.
|
|